CN117137821A - 一种去头屑多肽和洗发剂及其制备方法 - Google Patents
一种去头屑多肽和洗发剂及其制备方法 Download PDFInfo
- Publication number
- CN117137821A CN117137821A CN202311159305.2A CN202311159305A CN117137821A CN 117137821 A CN117137821 A CN 117137821A CN 202311159305 A CN202311159305 A CN 202311159305A CN 117137821 A CN117137821 A CN 117137821A
- Authority
- CN
- China
- Prior art keywords
- malassezia
- dandruff
- acorbine
- cosmetic
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001840 Dandruff Diseases 0.000 title claims abstract description 37
- 239000002453 shampoo Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 8
- 229920001184 polypeptide Polymers 0.000 title abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 7
- 241000555676 Malassezia Species 0.000 claims abstract description 45
- XSJMHPOUAORGMN-UWVGGRQHSA-N (2s)-5-amino-2-[[(2s)-5-amino-2-(3-aminopropanoylamino)pentanoyl]amino]pentanoic acid Chemical compound NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN)NC(=O)CCN XSJMHPOUAORGMN-UWVGGRQHSA-N 0.000 claims abstract description 44
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract description 13
- 208000008742 seborrheic dermatitis Diseases 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims description 22
- 239000002781 deodorant agent Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 206010056131 Tinea versicolour Diseases 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims description 7
- 208000007712 Tinea Versicolor Diseases 0.000 claims description 6
- 201000000508 pityriasis versicolor Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 206010016936 Folliculitis Diseases 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 18
- 238000012360 testing method Methods 0.000 abstract description 16
- 210000004761 scalp Anatomy 0.000 abstract description 14
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 239000012153 distilled water Substances 0.000 abstract description 5
- 238000005406 washing Methods 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 4
- 208000010201 Exanthema Diseases 0.000 abstract description 2
- 201000005884 exanthem Diseases 0.000 abstract description 2
- 206010037844 rash Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 50
- 238000009472 formulation Methods 0.000 description 39
- 241000555688 Malassezia furfur Species 0.000 description 17
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 16
- 210000004209 hair Anatomy 0.000 description 16
- 229960004125 ketoconazole Drugs 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 241000700199 Cavia porcellus Species 0.000 description 11
- 239000012071 phase Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 150000003505 terpenes Chemical class 0.000 description 7
- 235000007586 terpenes Nutrition 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 241000700198 Cavia Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 229940043810 zinc pyrithione Drugs 0.000 description 5
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 238000004332 deodorization Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- CGMOOAUESLSUKM-UHFFFAOYSA-N 2-benzylheptan-1-ol Chemical compound CCCCCC(CO)CC1=CC=CC=C1 CGMOOAUESLSUKM-UHFFFAOYSA-N 0.000 description 2
- LCVHZNSIAYNAGX-UHFFFAOYSA-N 2-ethylhexyl 3,5,5-trimethylhexanoate Chemical compound CCCCC(CC)COC(=O)CC(C)CC(C)(C)C LCVHZNSIAYNAGX-UHFFFAOYSA-N 0.000 description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical class CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- -1 conditioners Substances 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008686 ergosterol biosynthesis Effects 0.000 description 2
- 229940100549 ethylhexyl isononanoate Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940058690 lanosterol Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 150000003535 tetraterpenes Chemical class 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- WIIZWVCIJKGZOK-IUCAKERBSA-N 2,2-dichloro-n-[(1s,2s)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@@H](CO)[C@@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-IUCAKERBSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBWNKTZBTUKBOC-UHFFFAOYSA-N 3-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCCCO LBWNKTZBTUKBOC-UHFFFAOYSA-N 0.000 description 1
- WKDGGIHZTKEBIU-UHFFFAOYSA-N 3-hydroxypropyl undec-10-enoate Chemical compound C(CCCCCCCCC=C)(=O)OCCCO WKDGGIHZTKEBIU-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000193882 Corbicula Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101150106008 ERG11 gene Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 241001291477 Malassezia restricta Species 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 description 1
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960003344 climbazole Drugs 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000036758 dandruff formation Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 231100000314 skin damage score Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000021123 vacuolar acidification Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请涉及一种去头屑多肽和洗发剂及其制备方法,本申请首次公开通过头皮部或其他部位皮肤施用三肽Acorbine以及包括三肽Acorbine的洗护产品,对于马拉色菌具有非常好的抑制作用。在体外抑菌试验中,与对照组蒸馏水相比,其抑菌效果随着浓度的增加而显著增加,当浓度达到2%时,其体外抑制效果可达约93.2%。进而可以有效抑制马拉色菌的繁殖,减少头皮屑的产生,并且可以有效改善由马拉色菌引起的皮疹,脂溢性皮炎,起到良好的去屑止痒作用。
Description
技术领域
本发明属于化妆品技术领域,具体涉及一种去头屑多肽和洗发剂及其制备方法。
背景技术
头皮屑一般是指头皮上或头发里出现的薄片状鳞屑,并且经常伴有瘙痒。头皮屑是一种常见问题,全世界约有50%的成年人受到头皮屑的影响,男性也比女性更普遍。头皮屑开始于青春期,在大约20岁时达到发病率和严重程度的峰值,在超过50岁的人群中变得较少流行。
头皮屑是一团脱落的角质细胞,他们彼此之间保持较大的凝聚力并从角质层表面脱离。头皮屑的范围较难定义,因为头皮屑与脂溢性皮炎以及其它引起脱屑的皮肤病的界定并不清晰。很多学者认为头皮屑和脂溢性皮炎是同一疾病的不同阶段,头皮屑是脂溢性皮炎的轻症表现,不伴有特应性皮炎、银屑病、鱼鳞病以及其他的皮肤病,通常呈较小的干燥鳞片,而脂溢性皮炎是一种通常会超出头皮范围的更具炎症性的疾病,脱落的皮屑较大,粘着性高,也较为油腻。
目前学术界认为有3个主要因素决定了头皮屑的形成:马拉色菌增殖、头皮脂质分泌和个体易感性。这3个因素是相互关联的,它们决定了头皮屑的形成时间和表现形式。关于头皮屑的研究,目前较多的研究集中在马拉色菌的致病性上。
对于马拉色菌如何引起头皮屑的问题,大多数学者认为,马拉色菌源性磷脂酶和脂肪酶引起的不饱和脂肪酸聚集是引发炎症反应的关键。Plotkin等在体外实验中证明,糠秕马拉色菌可以产生磷脂酶A2,他认为马拉色菌属可能通过分泌磷脂酶A2来催化水解甘油三酯,产生花生四烯酸,且该催化作用可能通过类花生酸通路间接引发炎症反应。同时,马拉色菌源性脂肪酶降解皮脂中的甘油三酯,甘油三酯被水解为不饱和脂肪酸,皮肤在脂肪酸的刺激下,产生炎症反应。
嗜脂性马拉色菌以头皮上的脂质为营养来源,皮脂分泌旺盛,马拉色菌就会异常增殖,通过磷脂酶和脂肪酶的催化水解作用使得头皮中不饱和脂肪酸聚集,从而引发角质层炎症反应,炎症又导致头皮角质层的过度增生从而促使角质层细胞成块脱落,并引起皮肤屏障的损伤。
对患有头皮屑的头皮,其角质层中的结构脂类的含量明显降低,不同脂质之间的相对比值发生变化,并伴有组织结构损伤,经皮水分丢失明显高于健康头皮,说明了脂质水平的改变会影响头皮的屏障功能。头皮屏障受损后,外层角质细胞出现高度增殖的倾向,在外力作用下开始脱落,进一步引起头皮屏障的损伤,甚至出现亚临床的感染。
1874年,Malassez从头皮屑中分离出一种微生物,鉴定为卵形糠秕孢子菌,又称马拉色菌。后来,Unna(1887年)和Sabouraud(1904年)先后从头皮屑中分离出这种真菌。他们还发现头皮屑临床治疗结果的好坏与糠秕孢子菌是否减少或消失有关,因此认为该菌是引起头皮屑的病原菌,这一理论被后来的许多学者如Mcleod和Dowling(1928年)、Moore等(1936年)的研究所证实。
马拉色菌与多种皮肤病有关,包括花斑糠疹(PV)、马拉色菌毛囊炎(MF)、脂溢性皮炎(SD)和特应性皮炎(AD)。马拉色菌是感染性疾病PV和MF的直接致病因素,同时也是AD和SD的加重因素。马拉色菌脂肪酶水解甘油三酯产生的脂肪酸可引起皮肤炎症,导致脂溢性皮炎的发生。
常用的去屑产品中的去屑剂主要有三类:
角质剥脱剂:细胞生长抑制剂和抗真菌制剂。角质剥脱剂如水杨酸、硫磺和煤焦油,具有一定程度的剥脱角质的作用,但此类产品气味较差,刺激性强,长期使用会对角质层造成损伤。
细胞生长抑制剂:通过降低角质层细胞的更替速度改善角质化和脱屑症状,如二硫化硒,但其存在异味,用后使发质干涩,对于皮肤敏感者容易引起炎症反应。目前用于去屑止痒的产品多添加抗真菌制剂。
常用于抑制马拉色菌的抗真菌药物主要有酮康唑、氯咪巴唑、吡硫鎓锌(ZPT)等。唑类真菌抑制剂主要通过靶向ERG11基因编码的14'-羊毛甾醇脱甲基酶作用于麦角固醇生物合成,从而抑制羊毛甾醇转变为麦角固醇。使用唑类抗真菌制剂导致的麦角固醇生物合成减少会破坏液泡ATP酶的功能,从而破坏了细胞膜的完整性和通透性,导致液泡酸化和离子动态平衡受到破坏。唑类是真菌抑制剂,它们的长期使用可以使存活的真菌群体产生更大的耐药性,且唑类杀菌剂对藻类、鱼类等水生生物有毒害作用。
ZPT使马拉色菌细胞内锌水平显著提高,细胞锌的增加导致了SOD2基因的显著下调,从而破坏了Fe-S簇蛋白的合成,导致了线粒体功能障碍,从而诱导马拉色菌凋亡。ZPT能有效杀灭真菌、藻类,有较强的脱脂作用,但也容易诱发过敏性接触性皮炎,并且它的难溶性使得配制去屑产品时必须保证其不发生沉淀。这些问题的存在使得以上应用有一定的局限性。
近年来,随着环保、低碳、绿色和天然趋势的流行,植物来源的去屑产品成为研究的热点,并越来越受到人们的关注和喜爱。副作用小、来源广、价格低廉、较少出现耐药性,适合于长期及预防性应用的这些特点,使研究开发植物来源的去屑产品具有良好的前景。但由于植物提取物颜色深、气味重,并且成分复杂,其作用机制也不甚清晰,因此利用现代化的技术、工艺从天然植物中分离出有效的抗真菌成分,并研究其作用机理是新活性成分开发的方向。
具有抗菌性能的天然活性成分大多数具有特定化学基团,即酚类、萜烯类、生物碱类和多肽类,对引起疾病的微生物具有多种作用机制。具有抗菌性能的天然活性成分可分为以下四大类:
1.酚类,这是在植物界中分布最广泛的次生代谢产物。酚类化合物包含一个或多个直接与芳烃链相连的羟基,通常使用化学成分、羟基数、碳骨架上取代基数量等参数对酚类化合物进行分类。
2.萜烯类,它们是聚合的异戊二烯衍生物,其合成过程是通过以乙酸盐为起始单元的甲羟戊酸途径进行的。各种萜烯的分类基于其所含异戊二烯单元(C5)的数量。萜烯分为单萜烯(C10),倍半萜烯(C15),二萜烯(C20),酯基萜烯(C25),三萜烯(C30),四萜烯(C40)和多萜烯(C>40)。当萜烯含有一些的其他元素(通常为氧)时被称为萜类。
3.生物碱,即含氮的碱性有机化合物。除了碳、氢和氮,一些生物碱还可能含有氧、硫,很少含有氯、溴和磷等其他元素。生物碱和其他含氮的天然物质如氨基酸、核苷酸和胺之间没有明显的区别。
4.抗菌肽,植物抗菌肽(AMPs)是由不同植物产生的一组小分子蛋白质,是其防御机制的一部分。多数AMPs是含有10-60个氨基酸的多肽,其分子量范围为2-13kDa,通常是带螺旋结构的带正电荷的蛋白质。
由于天然植物活性成分存在巨大的化学多样性,这些化合物的作用机理尚不完全清楚。
东京大学生命科学与技术学院,Yohichi Tagawa课题组在《Biochemical andBiophysical Research Communications》(译作:生化和生物物理研究通讯)发表了文章Acorbine,a Corbicula japonicae derived tripeptide containing nonproteinogenicamino acids,suppresses ethanol-induced liver injury(译作:阿卡宾,一种来自日本的三肽,含有非蛋白原性氨基酸,抑制乙醇引起的肝损伤)。
文章指出,合成的Acorbine(β-丙氨酰-鸟氨酰-鸟氨酸)可治疗酒精引起的小鼠肝损伤。文章一并公开了Acorbine的提取工艺,如下:
凝胶渗透高效液相色谱在HPLC系统(日立,日本)上进行,使用Superdex PeptideHR 10/30(Amersham Biosciences,瑞典)色谱柱(10mm×30cm),流动相为250mM NaCl在20mm磷酸盐缓冲液(pH 7.2)中,室温(流速,0.25ml/min)。用205nm的吸光度监测洗脱。含Acorbine的部分用MWCO为500的Spectra/Por透析脱盐,冻干,然后用于结构分析。用高效液相色谱法测定的纯度为80.9%。
但是,现有专利和文献中并没有三肽Acorbine其他活性的报道。
发明内容
本发明专利申请对三肽Acorbine做了进一步的研究,发现其具有良好的皮肤外用安全性和马拉色菌抑制活性,可以作为去屑剂应用在洗发产品中。并进一步将其制备成洗发水等洗护用品,含有三肽Acorbine作为去屑剂的洗发水,具有良好的去屑效果。
本发明首先提供三肽Acorbine用于制备抑制马拉色菌化妆品的用途。
所述抑制马拉色菌化妆品的用途为去除头屑。
所述抑制马拉色菌化妆品的用途为改善斑糠疹(PV)。
所述抑制马拉色菌化妆品的用途为改善马拉色菌毛囊炎(MF)。
所述抑制马拉色菌化妆品的用途为改善脂溢性皮炎(SD)。
所述抑制马拉色菌化妆品的用途为去除改善特应性皮炎(AD)。
本申请所述的三肽Acorbine,可以根据现有技术提供的制备工艺制备,也可以直接购买获得。化学结构如下:
化学式:C13H27N5O4
分子量:317.21
m/z:317.21(100.0%),318.21(14.1%),318.20(1.8%)
元素分析:C,49.20;H,8.57;N,22.07;O,20.16。
更进一步的,本发明所述的三肽Acorbine,可以进一步制备成具有去头屑功效的洗发产品,例如洗发水,护发素等外用洗护产品。
所述洗护产品中含有三肽Acorbine的质量百分数为0.1%-2.0%。
包含三肽Acorbine的化妆品还包括助剂,以及其他功效成分的一种或几种。
本发明的有益效果:本申请所述三肽Acorbine以及包括三肽Acorbine的洗护产品通过头皮部或其他部位皮肤施用,对于马拉色菌具有非常好的抑制作用。在体外抑菌试验中,与对照组蒸馏水相比,其抑菌效果随着Acorbine浓度的增加而显著增加,当浓度达到2%时,其体外抑制效果可达约93.2%。可以有效抑制头部马拉色菌的繁殖,减少头皮屑的产生,并且可以有效改善由马拉色菌引起的皮疹,脂溢性皮炎,起到良好的去屑止痒作用。
附图说明:
附图1:试验动物给药示意图
具体实施方式
以下结合具体实施例来进一步说明本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
实施例1三肽Acorbine水溶液多次皮肤刺激试验(参照中国专利CN 102429846B测试方法实施)
1.1材料和方法
1、受试物为10%三肽Acorbine水溶液
2、受试动物:普通级白色新西兰种家兔4只
3、试验方法:试验前24h将动物背部脊柱两侧毛剃掉,剃毛范围左右各约3cm×3cm,试验时将受试物0.5mL均匀涂抹于左侧约2.5cm×2.5cm皮肤上,右侧用蒸馏水作对照。每天涂抹一次,连续7d。从第二天开始,每天涂抹前去毛,用温水清洗,1h后观察皮肤反应并进行皮肤刺激反应评分(评分标准为《化妆品安全技术规范》皮肤刺激反应评分表),试验结束后,分别计算14天总积分、14天每只动物积分均值,每天每只动物积分,如有必要对皮肤刺激反应进行分级判定。
1.2试验结果
表1多次皮肤刺激性试验结果
如上表数据可以看出,与对照组蒸馏水相比,10%三肽Acorbine水溶液涂抹于试验动物后,并未出现任何红斑,水肿等炎症现象,即说明在此浓度下的安全性明显优于现有角质剥脱剂或细菌生长抑制剂ZPT等。外用安全性良好。
实施例2Acorbine水溶液对限制马拉色菌及糠秕马拉色菌的药敏实验
2.1菌株
本实验中的限制马拉色菌标准株为限制马拉色菌(Malassezia restricta)CICC31847;糠秕马拉色菌标准株为糠秕马拉色菌(Malassezia furfur)GDMCC 2.181。
2.2药物
分别取0.1g,0.5g,1.0g,2.0g,5.0g,10.0g Acorbine,加水至100ml,配置不同浓度的Acorbine水溶液。
2.3 2%橄榄油琼脂平板培养基的配制
取2%(w/w)麦芽浸膏、0.01%(w/w)酵母浸膏、0.25%(w/w)单硬脂酸甘油脂、4%(w/w)葡萄糖、1%(w/w)蛋白胨、2%(w/w)琼脂、50mg/L氯霉素、300mg/L放线菌酮、2%(v/v)橄榄油,全部装入锥形瓶中,以蒸馏水定容至100ml,搅拌,使各成分充分混合,用电磁炉加热使其充分溶化,冷却后即成2%橄榄油琼脂平板培养基。用121℃高压灭菌15分钟。在超净工作台上,加热融化已备无菌的固体培养基,再趁热将培养基倒入无菌培养皿,这里应注意不要将培养皿外壁与锥形瓶口相接触造成污染,在每个培养皿中倒入约12mL融化的固体培养基,每个培养皿依次倒好后,立即盖上培养皿盖子,在超净工作台上静置约10分钟,让固体培养基冷却凝固,最后叠放好培养皿,备用。
2.4菌液的制备
分别将受试菌(限制马拉色菌、糠秕马拉色菌)连续传代培养2次,第2次35℃传代培养2天后,用无菌生理盐水洗脱纯化的菌落,制成菌悬液,并调整其至麦氏4号比浊管浓度。经血细胞计数板计数其菌含量为(1~2)×107CFU/ml。
2.5抑菌活性的测定
在无菌操作台上,将制备好的马拉色菌菌悬液稍微摇匀;2%橄榄油琼脂培养基平板全部水平放在无菌操作台上,右手持灭菌吸管在酒精灯旁保持无菌,吸取菌悬液,左手拇指和中指揭开培养皿盖,每个培养皿中滴入0.2ml菌悬液,用涂布棒将菌悬液涂布均匀,使菌悬液均匀密布于整个培养皿,加盖待其干燥2分钟后;右手持无菌镊子,每个平板上用无菌镊子放入灭菌牛津杯,牛津杯中分别加入上述2.2中制备的不同浓度的Acrbine水溶液100μl,然后放进35℃恒温培养箱中培养48h,设置3次重复,到达培养时间后用游标卡尺测量抑菌圈的直径d。
3.结果(牛津杯法)
不同浓度Acorbine水溶液对限制马拉色菌及糠秕马拉色菌标准菌株的抑菌圈结果见表2。
表2不同药液对两种马拉色菌菌株的抑菌圈直径(包括牛津杯直径8mm)
Acorbine水溶液 | 限制马拉色菌单位:mm | 糠秕马拉色菌单位:mm |
0.1% | 10.5 | 10.6 |
0.5% | 13.6 | 13.9 |
1.0% | 18.6 | 17.0 |
2.0% | 20.7 | 21.4 |
5.0% | 25.3 | 24.4 |
10.0% | 30.2 | 31.1 |
。
由以上结果可知,不同浓度Acorbine水溶液对限制马拉色菌和糠秕马拉色菌有较强的抑菌效果,其抑制效果,随着Acorbine浓度的增加而增大。
实施例3含有Acorbine的洗发水的制备(单位:g)
制备工艺:
步骤1)取处方量鳄梨油,依次加入3-羟丙基辛酸酯,单辛酸甘油酯,3-羟丙基十一碳烯酸酯,羟基苯乙酮,椰油酰单乙醇胺,加热,搅拌,溶解,得油相;
步骤2)取去离子水20ml,依次加入柠檬酸,Acorbine,椰油酰胺丙基甜菜碱,月桂醇聚醚硫醇酯钠,芦荟浓缩凝胶得水相,加热至油相温度,保温,备用;
步骤3)将步骤1)得到的油相,在搅拌条件下加入到步骤2)所得的水相中,保温,继续搅拌,使混合均匀;
步骤4)在步骤3)所得物料中加入处方量氯化钠,搅拌,使混合均匀;
步骤5)在步骤4)所得物料中加入余量去离子水,定容至100ml,降温至室温,即得。
实施例4含有Acorbine的护发素的制备(单位:g)
成分 | 配方1 | 配方2 | 配方3 | 配方4 |
鲸蜡硬脂醇 | 4.0 | 4.0 | 4.0 | 4.0 |
异壬酸乙基己酯 | 2.0 | 2.0 | 2.0 | 2.0 |
甘油硬脂酸酯 | 15 | 15 | 15 | 15 |
山嵛基三甲基氯化铵 | 1.0 | 1.0 | 1.0 | 1.0 |
苯基改性硅油SF 1550 | 0.1 | 0.1 | 0.1 | 0.1 |
Acorbine | 0.1 | 0.5 | 2.0 | / |
甘油 | 6.0 | 6.0 | 6.0 | 6.0 |
10%氢氧化钠溶液 | 0.4 | 0.4 | 0.4 | 0.4 |
柠檬香精 | 0.4 | 0.4 | 0.4 | 0.4 |
尼泊金甲酯 | 0.3 | 0.3 | 0.3 | 0.3 |
去离子水 | 加至100ml | 加至100ml | 加至100ml | 加至100ml |
。
制备工艺:
步骤1)取处方量鲸蜡硬脂醇,异壬酸乙基己酯,苯基改性硅油SF 1550,甘油硬脂酸酯,尼泊金甲酯,加热融化,为油相,保温,备用;
步骤2)取处方量Acorbine,甘油,柠檬香精,10%氢氧化钠溶液,山嵛基三甲基氯化铵,加入到适量去离子水中,形成水相,加热到与油相温度相同,备用;
步骤3)将步骤2)所得到的水相溶液,在真空搅拌条件下,加入到步骤1)所得到的油相中,搅拌均匀;
步骤4)加入去离子水定容至100ml,搅拌均匀,降温至室温,即得。
实施例5含有Acorbine的除臭喷雾剂的制备(单位:g)
成分 | 配方1 | 配方2 | 配方3 | 配方4 |
PEG-40-氢化蓖麻油 | 3.0 | 3.0 | 3.0 | 3.0 |
乙基己基甘油 | 0.2 | 0.2 | 0.2 | 0.2 |
乙醇 | 40 | 40 | 40 | 40 |
柠檬酸钠 | 0.5 | 0.5 | 0.5 | 0.5 |
一水柠檬酸 | 0.50 | 0.50 | 0.50 | 0.50 |
1,2-己二醇 | 0.3 | 0.3 | 0.3 | 0.3 |
Acorbine | 0.1 | 0.5 | 2.0 | / |
2-苄基庚醇 | 0.1 | 0.1 | 0.1 | 0.1 |
柠檬香精 | 0.74 | 0.74 | 0.74 | 0.74 |
去离子水 | 加至100ml | 加至100ml | 加至100ml | 加至100ml |
。
制备工艺:
步骤1)取处方量PEG-40-氢化蓖麻油,乙基己基甘油,1,2-己二醇,2-苄基庚醇,加入到处方量乙醇中,搅拌,溶解;
步骤2)取处方量一水柠檬酸,柠檬酸钠,Acorbine,柠檬香精,加入到适量去离子水中,搅拌,溶解;
步骤3)取步骤1)所得溶液,在搅拌条件下,缓慢加入到步骤所得溶液中,搅拌,形成均一,透明的溶液;
步骤4)加入去离子水,定容至100ml,即得。
实施例6实施例3-5样品对豚鼠皮肤马拉色菌感染模型的抑菌作用(参照CN113876862B实施)
6.1实验动物和菌株:
白色SPF级豚鼠60只,320g~350g,雄性,室温25±2℃条件下饲养。
糠秕马拉色菌标准株为糠秕马拉色菌(Malassezia furfur)GDMCC 2.181。
6.2主要试剂
实验样品:实施例3-5所制备的洗发水,护发素和除臭喷雾样品。
对照品:酮康唑溶于二甲基亚砜(MDSO),制备2.5%(w/v)溶液。
6.3动物造模制备
(1)菌悬液的制备:将糠秕马拉色菌标准株在固体培养基(配制方法同实施例2)上连续传代培养2次,以保证其活力。第2次32℃培养5天后,挑其菌落于0.9%生理盐水中,无菌吸管反复吹打,制成菌悬液,在血细胞记数板上记数,调整其终浓度为1×109/CFU/ml。
(2)豚鼠背部以宠物推毛器剔除长毛后,用脱毛蜡脱毛,形成一片5×5cm2左右的无毛区。
(3)脱毛24h后以粗砂纸在豚鼠背上均匀打磨,再以移液器将糠批马拉色菌100μL+玉米油100μL溶液逆毛发生长方向均匀涂于背部无毛区。每日1次,连续7日。
6.4动物模型评价指标:
(1)感染区皮损情况:观察红斑、鳞屑每项以0~3分计,计算各组每只豚鼠皮损总分(红斑+鳞屑)的平均值。
表10评分标准
(2)涂抹马拉色菌区皮肤真菌直接镜检阳性结果
分别于停止涂菌后的第7、14、21天取豚鼠涂抹马拉色菌区皮肤上皮屑,后用10%(w/v)氢氧化钾溶解角质后直接用显微镜检查,计算阳性率。
截止第21天,所有实验豚鼠均感染了秕糠马拉色菌(空白对照组除外),即造模成功。
6.5.分组及给药
常规饲养一周后,随机分组,每组10只。
A组:空白对照组,豚鼠10只常规饲养,无药物干预。
B组:豚鼠模型阳性对照组,造模成功后,次日继续常规饲养,无药物干预。
C组:实施例3洗发水配方1-4,造模成功后,次日在每只豚鼠背部已去毛标记处按附图1所示涂敷实施例3洗发水配方1-4,每次取药1mL,每日涂药2次,疗程3周,涂药时用医用胶带或其他具有隔离作用的薄膜,覆盖除给药部位的其他部位。
D组:实施例4护发素配方1-4,造模成功后,次日在每只豚鼠背部已去毛标记处按附图1所示涂敷实施例4护发素配方1-4,每次取药1mL,每日涂药2次,疗程3周,涂药时用医用胶带或其他具有隔离作用的薄膜,覆盖除给药部位的其他部位。
E组:实施例5除臭喷雾配方1-4,造模成功后,次日在每只豚鼠背部已去毛标记处按附图1所示涂敷实施例5除臭喷雾配方1-4,每次取药1mL,每日涂药2次,疗程3周,涂药时用医用胶带或其他具有隔离作用的薄膜,覆盖除给药部位的其他部位。
F组:2%酮康唑组,造模成功后,次日在每只豚鼠背部已去毛处标记处以2%(w/v)酮康唑洗剂外涂干预治疗,每次取药1mL,如不足,则继续取用,直至均匀涂敷。每日涂药2次,疗程3周,涂药时用医用胶带或其他具有隔离作用的薄膜,覆盖除给药部位的其他部位。
6.6实验疗效评价
6.6.1豚鼠皮肤感染区皮损评分
统计治疗第0天,7天,14天,21天皮损的积分情况。
6.6.2治疗后豚鼠皮肤感染区皮肤真菌转阴率
给药及皮损观察结束后,将实验各组豚鼠背部感染区皮肤用75%酒精棉球消毒,每只豚鼠剪下直径约1.5×1.5cm2圆形皮损1块,剪碎,置于装有2mL 0.9%生理盐水的玻璃匀浆器中,加入0.5%(v/v)吐温80,充分匀浆,使成混悬液,取300mL混悬液均匀涂布于马拉色菌固体培养基(配制方法同实施例2中的2.3)的圆形培养皿上,轻轻晃动培养皿,使其均匀分布于培养皿表面后32℃条件下静置培养3天,观察并记录其菌落数。如培养皿中的菌落数>1,则视其为阳性。三次重复。
真菌学转阴率=每组培养阴性数/每组感染动物总数×100%。
6.7实验结果
6.7.1实验各组皮损积分比较
由表11可见,实验分别对用药第0、7、14、21天豚鼠模型靶皮损进行评分,以重复测量方差分析评价不同时间点皮损评分的差异性。统计结果显示:随着治疗时间的延续,实施例3-5所制备的洗发水,护发素,除臭喷雾中不同处方、酮康唑洗剂组、模型组皮损评分均呈现出不同程度下降的趋势。与模型组比较,含有Acorbine浓度达到2%的洗发水,护发素,除臭喷雾,对皮损改善最为明显(p<0.01),并且略优于2.5%酮康唑组。
表11各组豚鼠皮损评分差异表
试验分组 | 治疗第0天 | 治疗第7天 | 治疗第14天 | 治疗第21天 |
空白对照 | 0 | 0 | 0 | 0 |
模型组 | 5.6±1.3 | 5.6±0.1 | 5.1±0.3 | 5.2±1.0 |
酮康唑组 | 5.8±0.5 | 3.9±0.9 | 2.1±0.9 | 1.3±0.5 |
实施例3配方1 | 5.7±0.6 | 4.1±0.9 | 2.8±0.2 | 2.3±0.5 |
实施例3配方2 | 5.1±0.2 | 3.7±0.6 | 2.2±0.2 | 1.5±0.3 |
实施例3配方3 | 5.7±1.2 | 3.3±1.1 | 1.9±1.2 | 1.2±0.9 |
实施例3配方4 | 5.1±0.2 | 4.7±1.3 | 4.3±0.5 | 4.6±1.4 |
实施例4配方1 | 5.2±0.4 | 4.3±0.1 | 2.8±1.1 | 2.4±0.2 |
实施例4配方2 | 5.3±0.7 | 4.1±1.4 | 1.9±0.6 | 1.3±0.6 |
实施例4配方3 | 5.5±0.2 | 3.6±0.1 | 1.5±0.1 | 1.1±0.7 |
实施例4配方4 | 5.7±1.1 | 5.7±1.2 | 5.1±0.3 | 4.7±1.1 |
实施例5配方1 | 5.7±1.0 | 3.9±0.8 | 3.2±0.3 | 2.1±0.8 |
实施例5配方2 | 5.2±1.2 | 3.7±0.7 | 2.5±1.3 | 1.5±1.4 |
实施例5配方3 | 5.5±0.5 | 3.5±0.9 | 2.0±1.4 | 1.2±0.9 |
实施例5配方4 | 5.4±0.8 | 5.6±1.2 | 5.5±1.1 | 5.1±0.6 |
。
6.7.2真菌治愈率
由表12可见,统计结果显示含有Acorbine浓度达到2%的洗发水,护发素,除臭喷雾,转阴率超过80%,高于2.5%酮康唑洗剂组转阴率70%,而模型组真菌学治愈率为0,给药组、阳性药物组与模型组之间具有显著统计学差异。
表12各组真菌学治愈率
实验分组 | 镜检阳性 | 镜检阴性 | 转阴率 |
空白对照 | / | / | / |
模型组 | 10 | 0 | 0 |
酮康唑组 | 3 | 7 | 70% |
实施例3配方1 | 3 | 7 | 70% |
实施例3配方2 | 3 | 7 | 70% |
实施例3配方3 | 1 | 9 | 90% |
实施例3配方4 | 10 | 0 | 0% |
实施例4配方1 | 3 | 7 | 70% |
实施例4配方2 | 3 | 7 | 70% |
实施例4配方3 | 1 | 9 | 90% |
实施例4配方4 | 10 | 0 | 0% |
实施例5配方1 | 3 | 7 | 70% |
实施例5配方2 | 2 | 8 | 80% |
实施例5配方3 | 1 | 9 | 90% |
实施例5配方4 | 10 | 0 | 0% |
。
6.8实验结果
上述实验表明实施例3-5所制备的含有Acorbine的洗发水,护发素和除臭喷雾具有良好的马拉色菌抑制效果。在对豚鼠马拉色菌感染模型靶皮损积分检测中,含有0.5%Acorbine的洗发水,护发素和除臭喷雾与酮康唑组均能有效减少皮损积分,但含有2%Acorbine的洗发水,护发素和除臭喷雾具有更好的改善皮损效果,皮损积分下降趋势及均值都较2.5%酮康唑组具有优势。
真菌学治愈率评价提示:实施例3-5所制备的含有Acorbine的洗发水,护发素和除臭喷雾与酮康唑都能有效抑制真菌(糠秕马拉色菌),并且含有2%Acorbine的洗发水,护发素和除臭喷雾真菌(糠秕马拉色菌)抑制效果显著优于2.5%酮康唑组。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (8)
1.Acorbine用于制备抑制马拉色菌化生长的化妆品的用途,其特征在于,所述Acorbine化学结构如下:
2.如权利要求1所述的用途,其特征在于,所述化妆品为去除头屑化妆品。
3.如权利要求1所述的用途,其特征在于,所述化妆品为改善斑糠疹的化妆品。
4.如权利要求1所述的用途,其特征在于,所述化妆品为改善马拉色菌毛囊炎的化妆品。
5.如权利要求1所述的用途,其特征在于,所述化妆品为改善脂溢性皮炎的化妆品。
6.如权利要求1所述的用途,其特征在于,所述化妆品为改善特应性皮炎的化妆品。
7.如权利要求1所述的用途,其特征在于,所述化妆品为洗发水,护发素,除臭喷雾中的一种。
8.如权利要求1-7任一所述的用途,其特征在于,所述化妆品中含有Acorbine的质量百分数为0.1%-2.0%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311159305.2A CN117137821A (zh) | 2023-09-10 | 2023-09-10 | 一种去头屑多肽和洗发剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311159305.2A CN117137821A (zh) | 2023-09-10 | 2023-09-10 | 一种去头屑多肽和洗发剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117137821A true CN117137821A (zh) | 2023-12-01 |
Family
ID=88911736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311159305.2A Pending CN117137821A (zh) | 2023-09-10 | 2023-09-10 | 一种去头屑多肽和洗发剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117137821A (zh) |
-
2023
- 2023-09-10 CN CN202311159305.2A patent/CN117137821A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105148253B (zh) | 皮肤黏膜抗菌组合物 | |
KR20070092095A (ko) | 소독용 조성물 및 이의 제조 및 이용 방법 | |
KR102059513B1 (ko) | 애엽 및 동충하초 추출물을 포함하는 항산화용 또는 주름 개선용 화장료 조성물 | |
JP7537767B2 (ja) | 熱損傷の治療におけるロドコッカスルーバー製品の使用 | |
WO2020182180A1 (zh) | 赤红球菌产品在治疗外阴白色病变中的用途 | |
CN109010124B (zh) | 一种海洋精粹妇科抑菌凝胶及其制备方法 | |
KR100682979B1 (ko) | 항균 감염증 및 항염증 작용에 대한 예방 치료용 조성물 및이를 이용하여 얻어진 무좀치료제 | |
CN109833431A (zh) | 一种抑菌凝胶及其制备方法 | |
WO2017080049A1 (zh) | 一种止痒软膏及其制备方法 | |
KR101433823B1 (ko) | 부챗말 추출물 또는 분획물을 이용한 피부 외용제 조성물 | |
Cam et al. | Treatment of dermatophytosis in young cattle with propolis and Whitfield's ointment | |
CN111973551A (zh) | 一种贻贝粘蛋白抑菌凝胶及其制备方法 | |
JP2019178170A (ja) | 抗微生物作用を備えた組成物の製造のためのパチョリ抽出物の使用 | |
CN117137821A (zh) | 一种去头屑多肽和洗发剂及其制备方法 | |
KR20070112553A (ko) | 천연 식물 추출물을 이용한 수생곰팡이 억제제 | |
CN113827594A (zh) | 一种基于固体分散技术的头皮抑菌消炎组合物及其制备方法 | |
HU186767B (en) | Process for producing compositions for treating dermatologicalanomalys | |
CN113230200A (zh) | 一种治疗细菌性皮肤病的软膏及其制备方法 | |
KR102488864B1 (ko) | 가자 추출물 및 애엽 추출물을 함유하는 피부세균총의 생장 조절 또는 피부 면역 강화용 조성물 | |
US9023405B2 (en) | Pharmaceutical composition using stryphnodendron extracts for treating HPV infections | |
JP5922857B2 (ja) | アレルギー性疾患の治療剤および/または予防剤 | |
US7494672B2 (en) | Use of guaiac wood for treating inflammation of the skin | |
CN115300576B (zh) | 一种治疗脚气脚癣的复方中药纳米凝胶及其制备方法 | |
WO2012093919A2 (ko) | 백혈병 치료용 조성물 및 몰약 추출물의 제조방법 | |
CN114767708B (zh) | 一种稳定的妇科抑菌组合物及妇科护理液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |